Endogenous cannabinoid ligands (endocannabinoids) produced by neurons, astrocytes, and microglial cells activate cannabinoid receptors, the molecular target for marijuana's bioactive ingredient ⌬ 9 -tetrahydrocannabinol. The molecular mechanism underlying the production of the most abundant endocannabinoid, 2-arachidonoylglycerol (2-AG), is unclear. A prevalent hypothesis proposes that activation of metabotropic receptors coupled to the phosphatidylinositol-specific phospholipase C and diacylglycerol (DG) lipase pathway will systematically lead to increases in 2-AG production. Here, we show that ATP increases 2-AG production by cultured microglial cells in a phosphatidylinositol-specific phospholipase C and DG lipase-dependent manner. However, efficacious activation of metabotropic P2Y purinergic receptors coupled to phosphatidylinositol-specific phospholipase C does not increase 2-AG production. This suggests that ionotropic, and not metabotropic, purinergic receptors control 2-AG production at an unexpected enzymatic step of its metabolic pathway. We show that activation of P2X7 ionotropic receptors, which are highly permeable to calcium, is necessary and sufficient to increase 2-AG production in microglial cells. We also show that the sustained rise in intracellular calcium induced by activation of P2X7 receptors directly increases DG lipase activity while inhibiting the activity of monoacylglycerol lipase, the enzyme that degrades 2-AG. This inverse sensitivity of DG lipase and monoacylglycerol lipase to calcium constitutes an original and efficient modality for sustained accumulation of 2-AG. Because prolonged increases in 2-AG amounts in brain parenchyma are thought to orchestrate neuroinflammation, the enzymatic steps involved in 2-AG synthesis and degradation by microglial cells constitute appealing targets for therapy aimed at controlling exacerbated neuroinflammation.
M
icroglial cells, the macrophages of the brain, express membrane receptors that sense signals produced by brain injury. For example, microglial cells express purinergic receptors that sense ATP released by reactive astrocytes and lysed cells (1) . At micromolar concentrations, ATP activates metabotropic P2Y receptors coupled to phosphatidylinositol-specific phospholipase C (PI-PLC) and ionotropic P2X receptors that modulate membrane potential (2) . As ATP reaches millimolar concentrations, a subset of purinergic receptors, P2X 7 , is activated, becoming highly permeable to cations, such as calcium, for prolonged periods (2, 3) . Activation of purinergic receptors on microglial cells changes their phenotype; they retract their processes and increase their rate of migration (1, (3) (4) (5) . They also release immune-related mediators, such as cytokines, chemokines, cytotoxins, and growth factors, all of which orchestrate neuroinflammatory responses (6, 7) . Because many neuropathological conditions are associated with exacerbated neuroinflammation (8) , the molecular machinery underlying the production of immune-related mediators released by microglial cells constitutes an appealing target for therapies aimed at reducing exacerbated neuroinflammation.
Traumatic brain injury and experimental autoimmune encephalomyelitis, both of which are associated with exacerbated neuroinflammation, lead to increased production of endocannabinoid (eCBs) in brain parenchyma (9, 10) . This increased eCB production is thought to prevent cell damage in multiple ways. Sustained activation of cannabinoid receptors (i) on neurons inhibits excitotoxicity (10) (11) (12) (13) , (ii) on endothelial cells induces hypotension and decreases edema (14) , and (iii) on microglial cells and other invading immune cells regulates their immune response (15, 16) . The cellular source of eCBs produced during neuroinflammation is unknown, although it likely involves microglial cells, for they produce Ϸ20-fold more eCBs than neurons and astrocytes (16) .
Several eCBs have been identified: arachidonoylethanolamide (anandamide), 2-arachidonoylglycerol (2-AG), homo-␥-linolenoylethanolamide, and docosatetraenoylethanolamide (17) (18) (19) . Evidence suggests that the phospholipase D pathway produces anandamide, homo-␥-linolenoylethanolamide, and docosatetraenoylethanolamide, whereas the PI-PLC-diacylglycerol (DG) lipase pathway produces 2-AG (17, 18) . eCBs are inactivated by different molecular mechanisms. Anandamide is hydrolyzed into arachidonic acid and ethanolamine by fatty acid amide hydrolase (20) , and 2-AG is hydrolyzed into arachidonic acid and glycerol by monoacylglycerol (MG) lipase (21) . The rate of eCB production and inactivation determines the extent and duration of eCB production. These rates are important, considering that the extent and duration of cannabinoid receptor activation likely determines the cellular function that is regulated. For example, activation of cannabinoid receptors for seconds induces short-term and long-term plasticity (22) (23) (24) , whereas activation of cannabinoid receptors for minutes or even hours regulates the extent of excitotoxicity and neuroinflammation (9, 13, 25) . Because the molecular mechanism that controls sustained eCB production is unknown, we sought to identify the receptors and enzymatic steps that control ATP-induced 2-AG production in microglial cells (16) . Incubation. Dishes or plates containing microglial cells were rinsed once with HB buffer (20 mM Hepes͞5 mM NaHCO 3 ͞120 mM NaCl͞5 mM KCl͞2 mM CaCl 2 ͞1 mM MgSO 4 ͞1 mM NaH 2 PO 4 ͞10 mM glucose) and placed on a shaking water bath at 37°C for a 30-min preincubation period. Cells were then stimulated by directly adding agents prepared in 10ϫ HB buffer and incubated for an additional 10 min.
Lipid Extraction and eCB Analysis. Amounts of eCBs in cells plated in 60-mm dishes were determined as described (26, 27) . In brief, placing dishes on ice and adding ice-cold methanol stopped incubations. Lipids were extracted with chloroform containing internal standards (200 pmol of [ 2 H 4 ]eCB). Organic phases were purified by open-bed silica gel chromatography followed by HPLC, and eCB amounts were determined by chemical ionization-GC͞MS by using isotope dilution as a quantification method.
PLC Activity. PLC activity was determined as described (28 (29) . Lipids were visualized with phosphomolybdic acid (10%), bands were scraped off, and radioactivity therein was determined.
Western Blot Analysis. Western blot analysis was performed as described (16) . In brief, cells grown in 60-mm dishes were lysed, and membrane protein fractions were collected by ultracentrifugation. Samples were electrophoresed (SDS͞PAGE), transferred to nitrocellulose, and immunoblotted by using antibody directed against the P2X 7 receptor (1:200, Alomone, Jerusalem).
Calcium Imaging. Calcium imaging was performed as described (30) . In brief, cells grown on coverslips placed in 24-well plates were incubated in HB buffer containing 5 M fura-2-acetoxymethyl ester (Molecular Probes) for 30 min at room temperature. Cells were placed in a perfusion chamber on the stage of an inverted microscope (Diaphot 200, Nikon) equipped with a 40ϫ͞1.3-numerical-aperture oil immersion objective. Fura-2 was excited by using a Lambda DG-4 filter system (Sutter Instruments, Novato, CA) at 340 and 380 nm and fluorescence emission collected at 510 Ϯ 20 nm by a bandpass filter. Acquisition of fluorescence and image analysis were performed by using a digital imaging system (R3, Inovision, Durham, NC). Ratios were collected at 2-s intervals. Drugs were added to the chamber under nonperfused conditions so that these conditions were similar to the ones used for analyzing eCB production and PI-PLC activation.
Results

P2X7 Receptors Control 2-AG Production by Microglia.
Under basal conditions, mouse microglial cells in primary culture produced low, yet clearly detectable amounts of 2-AG (7.0 Ϯ 0.8 pmol͞mg protein, n ϭ 112 individual culture dishes). The levels of anandamide, homo-␥-linolenoylethanolamide, or docosatetraenoylethanolamide were below detection limit. As shown (16) , millimolar concentrations of ATP significantly increased 2-AG production in microglial cells (Fig. 1a) , whereas anandamide, homo-␥-linolenoylethanolamide, and docosatetraenoylethanolamide amounts remained below detection limits. ATP increased 2-AG production in a time-dependent manner (Fig. 1b) . At 10 min, the EC 50 of this response was 1.2 mM (not shown), which is consistent with activation of P2X 7 receptors (1). To determine whether activation of P2X 7 receptors is sufficient to increase 2-AG production, we tested the effect of Bz-ATP, a selective P2X 7 receptor agonist (2). Bz-ATP (200 M) increased 2-AG production to the same extent as ATP (Fig. 1a) . Pretreatment of microglial cells with oxidized-ATP, a P2X 7 antagonist, abolished both the ATP-and Bz-ATP-increased 2-AG production ( Fig. 1  c and d) . In line with these results, we confirmed that microglial cells express P2X 7 receptor proteins ( Fig. 1e) (1, 31) . These results show that activation of P2X 7 receptors is both sufficient and necessary to increase 2-AG production in microglial cells.
ATP-Induced 2-AG Production Requires PI-PLC Activity.
Many studies have shown that PI-PLC activity is necessary for 2-AG production; yet, alternative pathways, such as the phospholipase D pathway, have been proposed (32) . Fig. 2a shows that the PI-PLC inhibitor U73122 abolished ATP-induced 2-AG production by microglia, whereas the phospholipase D inhibitor propranolol had no effect, confirming the evidence that PI-PLC is necessary for 2-AG production. Considering this latter result, and the fact that activation of calcium-permeable ionotropic receptors, such as N-methyl-Daspartate receptors, increase PI-PLC activity (33, 34) , we tested the hypothesis that activation of P2X 7 receptors on microglial cells increases PI-PLC activity. Thus, microglial cells were incubated with ATP and Bz-ATP, and the production of [ 3 H]IP, a product of PI-PLC, was measured. We obtained two unexpected results. We found that ATP only induced a small increase in [ 3 H]IP production and Bz-ATP had no significant effect (Fig.  2b) , thus ruling out the possibility that activation of P2X 7 receptors increases 2-AG production by merely increasing PI-PLC activity. We also found that ADP and UTP, two P2Y receptor agonists, significantly increased [ 3 H]IP production (Fig.  2b) , although they had no effect on 2-AG production (Fig. 1a) .
Together, these results suggest that stimulation of PI-PLC activity is not sufficient to increase 2-AG production, and basal PI-PLC activity provides enough DG for ATP-induced 2-AG production to occur. If this second point holds true, U73122 should reduce PI-PLC activity below its basal activity. Fig. 2b shows that this was indeed the case.
DG Kinase Restrains 2-AG Production.
Because an increase in PI-PLC activity does not lead to an increase in 2-AG production, microglial cells must express an enzyme that shunts the PI-PLCderived DG toward a different metabolic pathway. Such an enzyme could be DG kinase, an enzyme that yields phosphatidic acid by phosphorylating DG (35) . To test this hypothesis, we investigated the effect of a DG kinase inhibitor, DG kinase inhibitor I, on 2-AG production by microglial cells. When applied to microglial cells, DG kinase inhibitor I dramatically increased both basal 2-AG production (278 Ϯ 122% of basal 2-AG production) and AT P-induced 2-AG production (11,178 Ϯ 6,032% of basal) (both results are from n ϭ 3 independent experiments performed in duplicate). These results suggest that microglial cells express a constitutively active DG kinase that shunts the majority of the PI-PLC-derived DG toward phosphatidic acid. These results also indicate that ATP does not increase 2-AG production by inhibiting DG kinase, because 2-AG production induced by the combination of ATP plus DG kinase inhibitor I is more than additive.
ATP-Induced 2-AG Production Requires Sustained Rise in Intracellular
Calcium. Whereas many studies have shown that eCB production requires calcium (17, 18) , at least one study suggested that increased eCB production may occur independently of a rise in [Ca 2ϩ ] i (36) . We tested the effect of EGTA, a chelator of extracellular calcium, and BAPTA-AM, a chelator of intracellular calcium, on ATP-and Bz-ATP-induced 2-AG production to determine whether these responses require a rise in [Ca 2ϩ ] i and, if so, whether calcium was mobilized from extra-or intracellular compartments. EGTA inhibited both ATP-and Bz-ATP-induced 2-AG production, whereas BAPTA-AM only inhibited Bz-ATP-induced 2-AG production ( Fig. 3 a and b) . This result suggests that calcium from the extracellular milieu is clearly necessary for P2X 7 -induced 2-AG production, whereas the involvement of intracellular calcium is ambiguous.
To determine why ATP-and Bz-ATP-induced 2-AG production had different sensitivities toward BAPTA-AM, we used fura-2 imaging to monitor changes in [Ca 2ϩ ] i . It is known that activation of P2X 7 receptors leads to a sustained rise in [Ca 2ϩ ] i , a result of their high permeability to calcium, whereas activation of P2Y receptors induces a transient rise in [Ca 2ϩ ] i , due to the release of calcium from intracellular stores (2) . As expected, ATP induced a rise in [Ca 2ϩ ] i that was both rapid and sustained (Fig. 3c) (Fig. 3c) . On the other hand, Bz-ATP induced only a sustained increase in [Ca 2ϩ ] i that was abolished by EGTA and clearly reduced by BAPTA-AM (Fig. 3d) .
Together, these results suggest that increased 2-AG production induced by ATP and Bz-ATP requires sustained rise in [Ca 2ϩ ] i , likely the result of P2X 7 receptor activation, whereas transient elevations in [Ca 2ϩ ] i , likely mediated through P2Y receptors, are not sufficient to increase 2-AG production. BAPTA-AM did not prevent ATP-induced 2-AG production because this chelator does not efficiently prevent the ATPinduced sustained rise in [Ca 2ϩ ] i.
2-AG Production Is Controlled by Calcium-Dependent DG Lipase and
MG Lipase Activity. DG lipase is known to produce 2-AG by hydrolyzing DG (17, 18) . Indeed, the DG lipase inhibitor RHC-80267 prevented the ATP-increased 2-AG production in microglial cells (Fig. 4a) . To determine whether DG lipase activity constitutes an enzymatic step that controls 2-AG production, we measured DG lipase activity in microglial cell homogenates by quantifying the production of 2-[ 14 C]AG when adding DG that contains [ 14 C]arachidonic acid in its sn-2 position. In the same experiments, we indirectly measured MG lipase activity by quantifying the production of [ 14 C]arachidonic acid. Fig. 4b shows that, within minutes, large amounts of 2-[ 14 C]AG were generated under basal conditions. On the contrary, under these conditions, little [ 14 C]arachidonic acid was produced, suggesting that MG lipase is less active than DG lipase in microglial cell homogenates. 2-[ 14 C]AG production was significantly increased by calcium, slightly reduced by EGTA and significantly inhibited by RHC-80267 (Fig. 4c) , suggesting that calcium increases DG lipase activity. Remarkably, [ 14 C]arachidonic acid production was increased by both calcium and EGTA and inhibited by RHC-80267 (Fig. 4d) . The effect of calcium and RHC-80267 on [ 14 C]arachidonic acid production likely ref lects their effect on DG lipase. These results suggest that calcium inhibits MG lipase activity. We addressed this latter possibility by incubating microglial cell homogenates with 2-AG labeled with [ 3 H]arachidonic acid and measured the production of free [ 3 H]arachidonic acid as direct measure of MG lipase activity. Indeed, microglial cell homogenates express MG lipase activity (Fig. 4e) , which was not significantly affected by calcium and RHC-80267 but was increased by EGTA (Fig. 4f ) , confirming that MG lipase activity is inhibited by calcium.
Discussion
Our study identifies the purinergic receptor and enzymatic steps controlling 2-AG production in microglial cells. Fig. 5 depicts the model that we propose. Under basal conditions, microglial cells express constitutive PI-PLC activity, which continuously produces DG; yet, 2-AG production is low. Two mechanisms are likely to prevent 2-AG accumulation. DG kinase shunts the majority of the PI-PLC-produced DG toward phosphatidic acid, thus reducing substrate availability for DG lipase (Fig. 5a ). Although some DG may reach DG lipase and produce 2-AG, the latter is promptly hydrolyzed by MG lipase, which should be active at the low [Ca 2ϩ ] i present in intact cells (Fig. 5a) . Under conditions whereby PI-PLC activity is greatly increased, for example, when ADP or UTP activates P2Y receptors, DG kinase activity is still sufficient to shunt all the PI-PLC-produced DG (Fig. 5b) . Under conditions whereby P2X 7 receptors are activated, for example, by millimolar concentrations of ATP, the sustained rise in [Ca 2ϩ ] i that ensues increases DG lipase activity and decreases MG lipase activity, thus allowing 2-AG to accumulate (Fig. 5c ). This inverse sensitivity of two lipases to calcium constitutes an original and efficient modality for sustained accumulation of a signaling lipid.
RHC-80267 inhibits both ATP-induced 2-AG production by microglial cells and the calcium-sensitive DG lipase activity in microglial cell homogenates, confirming the evidence that DG lipase is absolutely necessary for 2-AG production (29, 32) . Although no DG lipase has been cloned to date, various studies have shown that more than one DG lipase entity exists and that these enzymes have different sensitivities toward calcium (37). Recently, MG lipase has been cloned (21) . Here, we show that the activity of this enzyme is inhibited by calcium.
Here, DG kinase is implicated in regulating eCB production. Nine DG kinase isoforms have been identified, each having a unique tissue and subcellular distribution (35) . We show that, in microglial cells, DG kinase actively shunts the majority of PI-PLC-produced DG from the DG lipase pathway. Indeed, DG kinase inhibitor I increases basal 2-AG production by 3-fold and the ATP-increased 2-AG production by 30-fold. Selective inhibition of the specific DG kinase isoform involved in this response would provide an appealing pharmacological tool to increase 2-AG production.
Activation of P2X 7 receptors results in a prolonged opening of its pore, which allows large quantities of extracellular calcium to enter the cell (2, 3) . In line with this evidence, we show that chelation of extracellular calcium by EGTA prevents ATP-and Bz-ATP-induced sustained rise in [Ca 2ϩ ] i . In the presence of EGTA, the rapid rise in [Ca 2ϩ ] i induced by ATP, which is likely due to activation of P2Y receptors, is not affected. In the presence of EGTA, both ATP-and Bz-ATP-induced 2-AG production are prevented, suggesting that 2-AG production is induced by a sustained rise in [Ca 2ϩ ] i coming from the extracellular space. Do sustained rises in [Ca 2ϩ ] i systematically increase 2-AG production? This seems to be the case. In macrophage-like cells, both platelet-activating factor and lipopolysaccharide induce sustained increases in [Ca 2ϩ ] i (38, 39) and increase 2-AG production (40, 41) . In neurons, activation of N-methyl-D-aspartate receptors enhance [Ca 2ϩ ] i and increase 2-AG production (29) . In support of the notion that sustained rises in [Ca 2ϩ ] i is required to increase 2-AG production, ADP and UTP, which transiently elevate [Ca 2ϩ ] i in microglial cells in a manner that is not affected by EGTA (data not shown), do not increase 2-AG production (Fig. 1a) .
Why did BAPTA-AM significantly affect Bz-ATP-induced 2-AG production, but it did not affect ATP-induced 2-AG production? When monitoring [Ca 2ϩ ] i we saw that BAPTA-AM prevented the Bz-ATP-induced rise in [Ca 2ϩ ] i , whereas it only reduced the ATP-induced rise in [Ca 2ϩ ] i . One likely explanation for this difference is that ATP also induces a release of calcium from intracellular stores (i.e., the initial rise in [Ca 2ϩ ] i ), which are replenished through calcium-operated calcium channels (38) . This strong influx of calcium is unlikely to be chelated by BAPTA-AM, because this chelator is likely to already be saturated by calcium. Thus, ATP still induces 2-AG production in the presence of BAPTA-AM because of the rise in [Ca 2ϩ ] i that remains.
Both ATP and 2-AG concurrently increase in brain parenchyma under neuropathological conditions (9, 10) . Our data provide a functional link between these two phenomena. Immunohistochemical studies show that microglial cells and astrocytes express P2X 7 receptors (1). Here, we show that activation of P2X 7 receptors on microglial cells increases 2-AG production, but recent experiments from our laboratory show that P2X 7 receptor activation on astrocytes in primary culture also increases 2-AG production (unpublished data). Note that microglial cells in primary culture produce Ϸ20-fold higher amounts of eCB (expressed in pmol͞mg of protein) compared with astrocytes in primary culture, but astrocytes in brain parenchyma are more abundant than microglial cells. Therefore, we propose that, under neuropathological conditions, microglial cells and astrocytes are responsible for producing a significant amount of the eCB that accumulates in brain parenchyma.
Can 2-AG control the extent of neuroinflammatory responses? As extracellular ATP concentrations increase to millimolar levels and activate P2X 7 receptors expressed by neural cells, local amounts of 2-AG will increase. 2-AG then activates presynaptic CB 1 receptors, which reduces glutamate releases and tempers excitotoxicity (11-13). 2-AG will also activate CB 1 receptors expressed by blood vessels, which will decrease cerebral blood flow and reduce edema expansion (14) . Finally, 2-AG will activate CB 2 receptors expressed by microglial cells and invading immune cells, which inhibits their ability to release cytotoxic agents (42) . Therefore, compounds that affect eCB production from microglial cells might constitute promising therapeutics to temper exacerbated neuroinflammatory responses and allied cell damage. 
